|
1
|
El Osta B, Behera M, Kim S, Berry LD, Sica
G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, et
al: Characteristics and outcomes of patients with metastatic
KRAS-mutant lung adenocarcinomas: The lung cancer mutation
consortium experience. J Thorac Oncol. 14:876–889. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moore AR, Rosenberg SC, McCormick F and
Malek S: RAS-targeted therapies: is the undruggable drugged? Nat
Rev Drug Discov. 19:533–552. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simanshu DK, Nissley DV and McCormick F:
RAS proteins and their regulators in human disease. Cell.
170:17–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prior IA, Hood FE and Hartley JL: The
frequency of ras mutations in cancer. Cancer Res. 80:2669–2974.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
Meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang H, Liang SQ, Schmid RA and Peng RW:
New horizons in KRAS-mutant lung cancer: Dawn after darkness. Front
Oncol. 9:9532019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naim MJ, Alam MJ, Ahmad S, Nawaz F,
Shrivastava N, Sahu M and Alam O: Therapeutic journey of
2,4-thiazolidinediones as a versatile scaffold: An insight into
structure activity relationship. Eur J Med Chem. 129:218–250. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bos JL: Ras oncogenes in human cancer: A
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
9
|
Prior IA, Lewis PD and Mattos C: A
comprehensive survey of Ras mutations in cancer. Cancer Res.
72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin G, Huang J, Petela J, Jiang H, Zhang
Y, Gong S, Wu J, Liu B, Shi J and Gao Y: Targeting small GTPases:
Emerging grasps on previously untamable targets, pioneered by KRAS.
Signal Transduct Target Ther. 8:2122023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Michalak DJ, Unger B, Lorimer E, Grishaev
A, Williams CL, Heinrich F and Lösche M: Structural and biophysical
properties of farnesylated KRas interacting with the chaperone
SmgGDS-558. Biophys J. 121:3684–3697. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeon H, Wang S, Song J, Gill H and Cheng
H: Update 2025: Management of non-small-cell lung cancer. Lung.
203:532025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang L, Guo Z, Wang F and Fu L: KRAS
mutation: From undruggable to druggable in cancer. Signal Transduct
Target Ther. 6:3862021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang F, Wang B, Wu M, Zhang L and Ji M:
Current status of KRAS G12C inhibitors in NSCLC and the potential
for combination with anti-PD-(L)1 therapy: A systematic review.
Front Immunol. 16:15091732025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uniyal P, Kashyap VK, Behl T, Parashar D
and Rawat R: KRAS mutations in cancer: Understanding signaling
pathways to immune regulation and the potential of immunotherapy.
Cancers (Basel). 17:7852025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parikh K, Banna G, Liu SV, Friedlaender A,
Desai A, Subbiah V and Addeo A: Drugging KRAS: Current perspectives
and state-of-art review. J Hematol Oncol. 15:1522022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamarsheh S, Groß O, Brummer T and Zeiser
R: Immune modulatory effects of oncogenic KRAS in cancer. Nat
Commun. 11:54392020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghimessy A, Radeczky P, Laszlo V, Hegedus
B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B and
Megyesfalvi Z: Current therapy of KRAS-mutant lung cancer. Cancer
Metastasis Rev. 39:1159–1177. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eser M, Hekimoglu G, Yarar MH, Canbek S
and Ozcelik M: KRAS G12C mutation in NSCLC in a small genetic
center: Insights into sotorasib therapy response potential. Sci
Rep. 14:265812024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bourne HR, Sanders DA and McCormick F: The
GTPase superfamily: A conserved switch for diverse cell functions.
Nature. 348:125–132. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bourne HR, Sanders DA and McCormick F: The
GTPase superfamily: Conserved structure and molecular mechanism.
Nature. 349:117–127. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scheffzek K, Ahmadian MR, Kabsch W,
Wiesmüller L, Lautwein A, Schmitz F and Wittinghofer A: The
Ras-RasGAP complex: Structural basis for GTPase activation and its
loss in oncogenic Ras mutants. Science. 277:333–338. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin P, Leighl NB, Tsao MS and Shepherd
FA: KRAS mutations as prognostic and predictive markers in
non-small cell lung cancer. J Thorac Oncol. 8:530–542. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adderley H, Blackhall FH and Lindsay CR:
KRAS-mutant non-small cell lung cancer: Converging small molecules
and immune checkpoint inhibition. EBioMedicine. 41:711–716. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matikas A, Mistriotis D, Georgoulias V and
Kotsakis A: Targeting KRAS mutated non-small cell lung cancer: A
history of failures and a future of hope for a diverse entity. Crit
Rev Oncol Hematol. 110:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shepherd FA, Domerg C, Hainaut P, Jänne
PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier
T, Seymour L, et al: Pooled analysis of the prognostic and
predictive effects of KRAS mutation status and KRAS mutation
subtype in early-stage resected non-small-cell lung cancer in four
trials of adjuvant chemotherapy. J Clin Oncol. 31:2173–2181. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Riely GJ, Kris MG, Rosenbaum D, Marks J,
Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al: Frequency
and distinctive spectrum of KRAS mutations in never smokers with
lung adenocarcinoma. Clin Cancer Res. 14:5731–5734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Redig AJ, Chambers ES, Lydon CA, Dahlberg
SE, Alden RS and Janne PA: Genomic complexity in KRAS mutant
non-small cell lung cancer (NSCLC) from never/light-smokers v
smokers. J Clin Oncol. 34 (15 Suppl):S90872016. View Article : Google Scholar
|
|
30
|
Ferrer I, Zugazagoitia J, Herbertz S, John
W, Paz-Ares L and Schmid-Bindert G: KRAS-mutant non-small cell lung
cancer: From biology to therapy. Lung Cancer. 124:53–64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Liu S, Deng J, Akbay EA, Hai J,
Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, et al:
Assessing therapeutic efficacy of MEK inhibition in a
KRASG12C-driven mouse model of lung cancer. Clin Cancer
Res. 24:4854–4864. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garassino MC, Marabese M, Rusconi P, Rulli
E, Martelli O, Farina G, Scanni A and Broggini M: Different types
of K-Ras mutations could affect drug sensitivity and tumour
behaviour in non-small-cell lung cancer. Ann Oncol. 22:235–237.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee B, Lee T, Lee SH, Choi YL and Han J:
Clinicopathologic characteristics of EGFR, KRAS, and ALK
alterations in 6,595 lung cancers. Oncotarget. 7:23874–23884. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H,
Ren-Heidenreich L, Shi B, Ren H, Chu X, et al: Coexistence of EGFR
with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A
comprehensive mutation profiling from 5125 Chinese cohorts. Br J
Cancer. 110:2812–2820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Skoulidis F and Heymach JV: Co-occurring
genomic alterations in non-small-cell lung cancer biology and
therapy. Nat Rev Cancer. 19:495–509. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Christensen JG, Olson P, Briere T, Wiel C
and Bergo MO: Targeting Krasg12c-mutant cancer with a
mutation-specific inhibitor. J Intern Med. 288:183–191. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haidar M and Jacquemin P: Past and future
strategies to inhibit membrane localization of the KRAS oncogene.
Int J Mol Sci. 22:131932021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tomasini P, Walia P, Labbe C, Jao K and
Leighl NB: Targeting the KRAS pathway in non-small cell lung
cancer. Oncologist. 21:1450–1460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gysin S, Salt M, Young A and McCormick F:
Therapeutic strategies for targeting ras proteins. Genes Cancer.
2:359–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spoerner M, Herrmann C, Vetter IR,
Kalbitzer HR and Wittinghofer A: Dynamic properties of the Ras
switch I region and its importance for binding to effectors. Proc
Natl Acad Sci USA. 98:4944–4949. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buhrman G, O'Connor C, Zerbe B, Kearney
BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL and
Mattos C: Analysis of binding site hot spots on the surface of Ras
GTPase. J Mol Biol. 413:773–789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ostrem JM, Peters U, Sos ML, Wells JA and
Shokat KM: K-Ras(G12C) inhibitors allosterically control GTP
affinity and effector interactions. Nature. 503:548–551. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shima F, Matsumoto S, Yoshikawa Y,
Kawamura T, Isa M and Kataoka T: Current status of the development
of Ras inhibitors. J Biochem. 158:91–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Berndt N, Hamilton AD and Sebti SM:
Targeting protein prenylation for cancer therapy. Nat Rev Cancer.
11:775–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zimmermann G, Papke B, Ismail S, Vartak N,
Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens
PI and Waldmann H: Small molecule inhibition of the KRAS-PDEδ
interaction impairs oncogenic KRAS signalling. Nature. 497:638–642.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Riely GJ, Johnson ML, Medina C, Rizvi NA,
Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W and
Ginsberg MS: A phase II trial of Salirasib in patients with lung
adenocarcinomas with KRAS mutations. J Thorac Oncol. 6:1435–1437.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Whyte DB, Kirschmeier P, Hockenberry TN,
Nunez-Oliva I, James L, Catino JJ, Bishop WR and Pai JK: K- and
N-Ras are geranylgeranylated in cells treated with farnesyl protein
transferase inhibitors. J Biol Chem. 272:14459–14464. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shima F, Yoshikawa Y, Ye M, Araki M,
Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, et al: In
silico discovery of small-molecule Ras inhibitors that display
antitumor activity by blocking the Ras-effector interaction. Proc
Natl Acad Sci USA. 110:8182–8187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gerber DE, Camidge DR, Morgensztern D,
Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni
PP, Zhang S, et al: Phase 2 study of the focal adhesion kinase
inhibitor defactinib (VS-6063) in previously treated advanced KRAS
mutant non-small cell lung cancer. Lung Cancer. 139:60–67. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cox AD, Fesik SW, Kimmelman AC, Luo J and
Der CJ: Drugging the undruggable RAS: Mission possible? Nat Rev
Drug Discov. 13:828–851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang M and Casey PJ: Protein prenylation:
Unique fats make their mark on biology. Nat Rev Mol Cell Biol.
17:110–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kazi A, Xiang S, Yang H, Chen L, Kennedy
P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, et al:
Dual farnesyl and geranylgeranyl transferase inhibitor thwarts
mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer
Res. 25:5984–5996. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tao MH, Chen S, Freudenheim JL, Cauley JA,
Johnson KC, Mai X, Sarto GE, Wakelee H, Boffetta P and
Wactawski-Wende J: Oral bisphosphonate use and lung cancer
incidence among postmenopausal women. Ann Oncol. 29:1476–1485.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nagao S, Hattori N, Fujitaka K, Iwamoto H,
Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H and Kohno N:
Regression of a primary pulmonary adenocarcinoma after zoledronic
acid monotherapy. Hiroshima J Med Sci. 60:7–9. 2011.PubMed/NCBI
|
|
58
|
Kitai H, Ebi H, Tomida S, Floros KV,
Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC and Yano S:
Epithelial-to-mesenchymal transition defines feedback activation of
receptor tyrosine kinase signaling induced by MEK inhibition in
KRAS-mutant lung cancer. Cancer Discov. 6:754–769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Johnson C, Burkhart DL and Haigis KM:
Classification of KRAS-activating mutations and the implications
for therapeutic intervention. Cancer Discov. 12:913–923. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hunter JC, Manandhar A, Carrasco MA,
Gurbani D, Gondi S and Westover KD: Biochemical and structural
analysis of common cancer-associated KRAS mutations. Mol Cancer
Res. 13:1325–1335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ostrem JML and Shokat KM: Direct
small-molecule inhibitors of KRAS: From structural insights to
mechanism-based design. Nat Rev Drug Discov. 15:771–785. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Canon J, Rex K, Saiki AY, Mohr C, Cooke K,
Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, et al: The
clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature. 575:217–223. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pandey D, Chauhan SC, Kashyap VK and Roy
KK: Structural insights into small-molecule KRAS inhibitors for
targeting KRAS mutant cancers. Eur J Med Chem. 277:1167712024.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Warnecke B and Nagasaka M: Adagrasib in
the treatment of KRAS p.G12C positive advanced NSCLC: Design,
development and place in therapy. Drug Des Devel Ther.
18:5673–5683. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li Z, Song Z, Zhao Y, Wang P, Jiang L,
Gong Y, Zhou J, Jian H, Dong X, Zhuang W, et al: D-1553
(Garsorasib), a potent and selective inhibitor of
KRASG12C in patients with NSCLC: Phase 1 study results.
J Thorac Oncol. 18:940–951. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
D'Alessio-Sands L, Gaynier J,
Michel-Milian V, Agbowuro AA and Brackett CM: Current strategies
and future dimensions in the development of KRAS inhibitors for
targeted anticancer therapy. Drug Dev Res. 86:e700422025.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Deming DA: Development of KRAS inhibitors
and their role for metastatic colorectal cancer. J Natl Compr Canc
Netw. 23:e2470672025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao T and Liang SH: Novel tricyclic KRAS
inhibitors for the treatment of cancer. ACS Med Chem Lett.
16:178–179. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hong DS, Fakih MG, Strickler JH, Desai J,
Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS,
et al: KRASG12C inhibition with sotorasib in advanced
solid tumors. N Engl J Med. 383:1207–1217. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
No authors listed. FDA approves first KRAS
inhibitor: Sotorasib. Cancer Discov. 11:OF42021. View Article : Google Scholar
|
|
71
|
Skoulidis F, Li BT, Dy GK, Price TJ,
Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F,
et al: Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl
J Med. 384:2371–2381. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jänne PA, Riely GJ, Gadgeel SM, Heist RS,
Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, et
al: Adagrasib in non-small-cell lung cancer harboring a
KRASG12C mutation. N Engl J Med. 387:120–131. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
de Langen AJ, Johnson ML, Mazieres J,
Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H,
Skoulidis F, et al: Sotorasib versus docetaxel for previously
treated non-small-cell lung cancer with KRASG12C
mutation: A randomised, open-label, phase 3 trial. Lancet.
401:733–746. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wislez M, Mascaux C, Cadranel J, Thomas
QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V,
Rousseau-Bussac G, et al: Real-world effectiveness and tolerability
of sotorasib in patients with KRAS G12C-mutated metastatic
non-small cell lung cancer: The IFCT-2102 lung KG12Ci study. Eur J
Cancer. 219:1153012025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ou SHI, Jänne PA, Leal TA, Rybkin II,
Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL,
Cilliers C, et al: First-in-human phase I/IB dose-finding study of
adagrasib (MRTX849) in patients with advanced KRASG12C
solid tumors (KRYSTAL-1). J Clin Oncol. 40:2530–2538. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mok TSK, Yao W, Duruisseaux M, Doucet L,
Azkárate Martínez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de
Marinis F, et al: KRYSTAL-12: Phase 3 study of adagrasib versus
docetaxel in patients with previously treated advanced/metastatic
non-small cell lung cancer (NSCLC) harboring a KRASG12C
mutation. J Clin Oncol. 42 (Suppl 17):LBA85092024. View Article : Google Scholar
|
|
77
|
Li Z, Dang X, Huang D, Jin S, Li W, Shi J,
Wang X, Zhang Y, Song Z, Zhang J, et al: Abstract CT246:
Open-label, single-arm, multicenter, phase 2 trial of garsorasib in
KRAS G12C-mutated non-small-cell lung cancer. Cancer Res. 84 (7
Suppl):CT2462024. View Article : Google Scholar
|
|
78
|
Li Z, Dang X, Huang D, Jin S, Li W, Shi J,
Wang X, Zhang Y, Song Z, Zhang J, et al: Garsorasib in patients
with KRASG12C-mutated non-small-cell lung cancer in
China: An open-label, multicentre, single-arm, phase 2 trial.
Lancet Respir Med. 12:589–598. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Awad MM, Liu S, Rybkin II, Arbour KC,
Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, et al:
Acquired resistance to KRASG12C inhibition in cancer. N
Engl J Med. 384:2382–2393. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cox AD and Der CJ: ‘Undruggable KRAS’:
Druggable after all. Genes Dev. 39:132–162. 2025.PubMed/NCBI
|
|
81
|
Maruyama K, Shimizu Y, Nomura Y, Oh-Hara
T, Takahashi Y, Nagayama S, Fujita N and Katayama R: Mechanisms of
KRAS inhibitor resistance in KRAS-mutant colorectal cancer
harboring Her2 amplification and aberrant KRAS localization. NPJ
Precis Oncol. 9:42025. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mugarza E, van Maldegem F, Boumelha J,
Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P,
Romero-Clavijo P, et al: Therapeutic KRASG12C inhibition
drives effective interferon-mediated antitumor immunity in
immunogenic lung cancers. Sci Adv. 8:eabm87802022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Garassino MC, Jänne PA, Barlesi F, Spira
AI, Mok TSK, Hochmair M, O'Byrne KJ, Felip E, Kim SW, Cappuzzo F,
et al: 1394TiP KRYSTAL-7: A phase III study of first-line adagrasib
plus pembrolizumab versus pembrolizumab alone in patients with
advanced NSCLC with KRASG12C mutation mutation. Ann Oncol. 35
(Suppl 2):S872–S873. 2024. View Article : Google Scholar
|
|
84
|
Li BT, Falchook GS, Durm GA, Burns TF,
Skoulidis F, Ramalingam SS, Spira A, Bestvina CM, Goldberg SB,
Veluswamy R, et al: OA03.06 CodeBreaK 100/101: First report of
safety/efficacy of sotorasib in combination with pembrolizumab or
atezolizumab in advanced KRAS p.G12C NSCLC. J Thorac Oncol. 17
(Suppl):S10–S11. 2022. View Article : Google Scholar
|
|
85
|
Ernst SM, Hofman MM, van der Horst TE,
Paats MS, Heijboer FWJ, Aerts JGJV, Dumoulin DW, Cornelissen R, von
der Thüsen JH, de Bruijn P, et al: Hepatotoxicity in patients with
non-small cell lung cancer treated with sotorasib after prior
immunotherapy: A comprehensive clinical and pharmacokinetic
analysis. EBioMedicine. 102:1050742024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chour A, Basse C, Lebossé F, Bonte PE,
Girard N and Duruisseaux M: Management of sotorasib-related adverse
events and hepatotoxicities following anti-PD-(L)1 therapy:
Experience with sotorasib in two French anti-cancer centers and
practical guidance proposal. Lung Cancer. 191:1077892024.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang J, Johnson M, Barve M, Bazhenova L,
McCarthy M, Schwartz R, Horvath-Walsh E, Velastegui K, Qian C and
Spira A: Practical guidance for the management of adverse events in
patients with KRASG12C-mutated non-small cell lung cancer receiving
adagrasib. Oncologist. 28:287–296. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mina SA, Shanshal M, Leventakos K and
Parikh K: Emerging targeted therapies in non-small-cell lung cancer
(NSCLC). Cancers (Basel). 17:3532025. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fancelli S, Petroni G, Pillozzi S and
Antonuzzo L: Unconventional strategy could be the future: From
target to KRAS broad range treatment. Heliyon. 10:e297392024.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Masfarre Pinto L, Parreira ASDFM, Castro
Unanua N, Rocha P, Morilla Ruiz I, Teijeira Sanchez L, Clave S,
Navarro Gorro N, Bach Mora R, Sánchez I, et al: 1408P Differences
on immune biomarkers between KRAS G12C and KRAS non-G12C mutated
non-small cell lung cancer. Ann Oncol. 34 (Suppl2):S805–S806. 2023.
View Article : Google Scholar
|
|
91
|
Zhou C, Li C, Luo L, Li X, Jia K, He N,
Mao S, Wang W, Shao C, Liu X, et al: Anti-tumor efficacy of
HRS-4642 and its potential combination with proteasome inhibition
in KRAS G12D-mutant cancer. Cancer Cell. 42:1286–1300.e8. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li Y, Zhao J and Li Y: New exploration of
KRASG12D inhibitors and the mechanisms of resistance.
Exp Hematol Oncol. 14:392025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Arbour KC, Rizvi H, Plodkowski AJ,
Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG,
Arcila ME, et al: Treatment outcomes and clinical characteristics
of patients with KRAS-G12C-mutant non-small cell lung cancer. Clin
Cancer Res. 27:2209–2215. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bironzo P, Cani M, Jacobs F, Napoli VM,
Listì A, Passiglia F, Righi L, Di Maio M, Novello S and Scagliotti
GV: Real-world retrospective study of KRAS mutations in advanced
non-small cell lung cancer in the era of immunotherapy. Cancer.
129:1662–1671. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor mutational burden as an independent predictor of response to
immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: Results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Rothschild SI: KRAS and immune checkpoint
inhibitors-serendipity raising expectations. J Thorac Oncol.
14:951–954. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Torralvo J, Friedlaender A, Achard V and
Addeo A: The activity of immune checkpoint inhibition in KRAS
mutated non-small cell lung cancer: A single centre experience.
Cancer Genomics Proteomics. 16:577–582. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Mok TSK, Lopes G, Cho BC, Kowalski DM,
Kasahara K, Wu YL, de Castro G Jr, Turna HZ, Cristescu R,
Aurora-Garg D, et al: Associations of tissue tumor mutational
burden and mutational status with clinical outcomes in KEYNOTE-042:
Pembrolizumab versus chemotherapy for advanced PD-L1-positive
NSCLC. Ann Oncol. 34:377–388. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Gadgeel S, Rodriguez-Abreu D, Felip E,
Esteban E, Speranza G, Reck M, Hui R, Boyer M, Garon EB, Horinouchi
H, et al: LBA5-KRAS mutational status and efficacy in KEYNOTE-189:
Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus
chemo as first-line therapy for metastatic non-squamous NSCLC. Ann
Oncol. 30 (Suppl 11):xi64–xi65. 2019. View Article : Google Scholar
|
|
102
|
Peng L, Guo J, Kong L, Huang Y, Tang N,
Zhang J, Wang M, He X, Li Z, Peng Y, et al: Efficacy of
immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in
a Chinese population. Front Oncol. 12:10707612023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Urtecho SB, Provenzano L, Spagnoletti A,
Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla
M, Occhipinti M, et al: Decoding KRAS mutation in non-small cell
lung cancer patients receiving immunotherapy: A retrospective
institutional comparison and literature review. Lung Cancer.
199:1080512025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Koyama S, Akbay EA, Li YY, Aref AR,
Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM,
Denning WL, et al: STK11/LKB1 deficiency promotes neutrophil
recruitment and proinflammatory cytokine production to suppress
T-cell Activity in the lung tumor microenvironment. Cancer Res.
76:999–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Knetki-Wróblewska M, Wojas-Krawczyk K,
Krawczyk P and Krzakowski M: Emerging insights into STK11, KEAP1
and KRAS mutations: Implications for immunotherapy in patients with
advanced non-small cell lung cancer. Transl Lung Cancer Res.
13:3718–3730. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wei K, Sun T, Feng X, Chen Y, Liu Q and
Tang H: PD-1/L1 immune checkpoint inhibitors for KRAS-mutant
non-small cell lung cancer: A multicenter retrospective real-world
study. BMC Cancer. 25:4442025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Dong ZY and Wu YL: What is the
significance of TP53 and KRAS mutation for immunotherapy in
non-small cell lung cancer? Transl Cancer Res. 6 (Suppl
6):S1115–S1117. 2017. View Article : Google Scholar
|
|
108
|
Budczies J, Romanovsky E, Kirchner M,
Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R,
Stiewe T, et al: KRAS and TP53 co-mutation predicts benefit of
immune checkpoint blockade in lung adenocarcinoma. Br J Cancer.
131:524–533. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Bischoff P, Reck M, Overbeck T,
Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J,
Kemper M, Reinmuth N, et al: Outcome of first-line treatment with
pembrolizumab according to KRAS/TP53 mutational status for
nonsquamous programmed death-ligand 1-high (≥50%) NSCLC in the
German national network genomic medicine lung cancer. J Thorac
Oncol. 19:803–817. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Sun L, Handorf EA, Zhou Y, Borghaei H,
Aggarwal C and Bauman J: Outcomes in patients treated with
frontline immune checkpoint inhibition (ICI) for advanced NSCLC
with KRAS mutations and STK11/KEAP1 comutations across PD-L1
levels. Lung Cancer. 190:1075102024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ricciuti B and Garassino MC: Precision
immunotherapy for STK11/KEAP1-mutant NSCLC. J Thorac Oncol.
19:877–882. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
De Giglio A, De Biase D, Favorito V,
Maloberti T, Di Federico A, Zacchini F, Venturi G, Parisi C,
Gustavo Dall'Olio F, Ricciotti I, et al: STK11 mutations correlate
with poor prognosis for advanced NSCLC treated with first-line
immunotherapy or chemo-immunotherapy according to KRAS, TP53,
KEAP1, and SMARCA4 status. Lung Cancer. 199:1080582025. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Negrao MV, Paula AG, Molkentine D, Hover
L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters
L, et al: Impact of co-mutations and transcriptional signatures in
non-small cell lung cancer patients treated with adagrasib in the
KRYSTAL-1 trial. Clin Cancer Res. 31:1069–1081. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Olsen A, Lebedeva A, Nosova P, Nikulin V,
Sharova M, Ignatova E, Mileyko V and Ivanov M: Impact of the
STK11/KRAS co-mutation on the response to immunotherapy in a
real-world pan-cancer cohort. Tumori. 110:146–152. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sisca L, Cascetta P, Aijaz A, Catania C,
Facchinetti F, Naqash AR, Ricciuti B and Cortellini A: KRAS and
STK11 co-mutations in resectable non-small cell lung cancer:
Enduring prognostic value and impaired immunotherapy response.
Transl Lung Cancer Res. 14:2374–2382. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hellyer JA, Padda SK, Diehn M and Wakelee
HA: Clinical implications of KEAP1-NFE2L2 mutations in NSCLC. J
Thorac Oncol. 16:395–403. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Tian L, Liu C, Zheng S, Shi H, Wei F,
Jiang W, Dong Y, Xu H, Yin E, Sun N, et al: KEAP1 mutations as key
crucial prognostic biomarkers for resistance to KRAS-G12C
inhibitors. J Transl Med. 23:822025. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Jänne PA, van den Heuvel MM, Barlesi F,
Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido
P, et al: Selumetinib plus docetaxel compared with docetaxel alone
and progression-free survival in patients with KRAS-mutant advanced
non-small cell lung cancer. JAMA. 317:1844–1853. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sreter KB, Catarata MJ, von Laffert M and
Frille A: Resistance to KRAS inhibition in advanced non-small cell
lung cancer. Front Oncol. 14:13578982024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Blaquier JB, Cardona AF and Recondo G:
Resistance to KRASG12C inhibitors in non-small cell lung
cancer. Front Oncol. 11:7875852021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Cascetta P, Marinello A, Lazzari C,
Gregorc V, Planchard D, Bianco R, Normanno N and Morabito A: KRAS
in NSCLC: State of the art and future perspectives. Cancers
(Basel). 14:54302022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chour A, Toffart AC, Berton E and
Duruisseaux M: Mechanisms of resistance to KRASG12C inhibitors in
KRASG12C-mutated non-small cell lung cancer. Front Oncol.
14:13287282024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J,
Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, et al:
Clinical acquired resistance to KRASG12C inhibition
through a novel KRAS switch-II pocket mutation and polyclonal
alterations converging on RAS-MAPK reactivation. Cancer Discov.
11:1913–1922. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Mohanty A, Nam A, Srivastava S, Jones J,
Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, et al:
Acquired resistance to KRAS G12C small-molecule inhibitors via
genetic/nongenetic mechanisms in lung cancer. Sci Adv.
9:eade38162023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Akhave NS, Biter AB and Hong DS:
Mechanisms of resistance to KRASG12C-targeted therapy.
Cancer Discov. 11:1345–1352. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Labrie M, Brugge JS, Mills GB and
Zervantonakis IK: Therapy resistance: Opportunities created by
adaptive responses to targeted therapies in cancer. Nat Rev Cancer.
22:323–339. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Seo KY, Jelinsky SA and Loechler EL:
Factors that influence the mutagenic patterns of DNA adducts from
chemical carcinogens. Mutat Res. 463:215–246. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Goulding RE, Chenoweth M, Carter GC, Boye
ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH,
et al: KRAS mutation as a prognostic factor and predictive factor
in advanced/metastatic non-small cell lung cancer: A systematic
literature review and meta-analysis. Cancer Treat Res Commun.
24:1002002020.PubMed/NCBI
|
|
131
|
Awad MM, Gadgeel SM, Borghaei H, Patnaik
A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan
M, et al: Long-term overall survival from KEYNOTE-021 cohort G:
Pemetrexed and carboplatin with or without pembrolizumab as
first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol.
16:162–168. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Feng W: Advancements in targeted therapies
based on the EGFR, and KRAS genetic mutations in lung cancer. Theor
Nat Sci. 67:22–29. 2024. View Article : Google Scholar
|
|
133
|
Harris E and Thawani R: Current
perspectives of KRAS in non-small cell lung cancer. Curr Probl
Cancer. 51:1011062024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Jiang Z: A review of KRAS inhibitors and
potential improvement in the future. Transact Mater Biotechnol Life
Sci. 7:322–327. 2024.
|
|
135
|
Ricciuti B, Leonardi GC, Metro G, Grignani
F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A,
Zicari D and Crinò L: Targeting the KRAS variant for treatment of
non-small cell lung cancer: Potential therapeutic applications.
Expert Rev Respir Med. 10:53–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Rosner S, Connor S, Sanber K, Zahurak M,
Zhang T, Gurumurthy I, Zeng Z, Presson B, Singh D, Rayes R, et al:
Divergent clinical and immunologic outcomes based on STK11
co-mutation status in resectable KRAS-mutant lung cancers following
neoadjuvant immune checkpoint blockade. Clin Cancer Res.
31:339–351. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Choi J, Goulding SP, Conn BP, McGann CD,
Dietze JL, Kohler J, Lenkala D, Boudot A, Rothenberg DA, Turcott
PJ, et al: Systematic discovery and validation of T cell targets
directed against oncogenic KRAS mutations. Cell Rep Methods.
1:1000842021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Gondal MN, Cieslik M and Chinnaiyan AM:
Integrated cancer cell-specific single-cell RNA-seq datasets of
immune checkpoint blockade-treated patients. Sci Data. 12:1392025.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Álvarez-Pérez JC, Sanjuán-Hidalgo J,
Arenas AM, Hernández-Navas I, Benitez-Cantos MS, Andrades A,
Calabuig-Fariñas S, Jantus-Lewintre E, Paz-Ares L, Ferrer I and
Medina PP: High-fidelity Cas9-mediated targeting of KRAS driver
mutations restrains lung cancer in preclinical models. Nat Commun.
16:70802025. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wang Y, Bui TA, Yang X, Hutvagner G and
Deng W: Advancements in gene therapies targeting mutant KRAS in
cancers. Cancer Metastasis Rev. 44:242025. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Rodríguez-Abreu D, Powell SF, Hochmair MJ,
Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M,
Cheng SY, et al: Pemetrexed plus platinum with or without
pembrolizumab in patients with previously untreated metastatic
nonsquamous NSCLC: Protocol-specified final analysis from
KEYNOTE-189. Ann Oncol. 32:881–895. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Garassino MC, Theelen WSME, Jänne PA, Boom
LN, De Marinis F, Dómine Gómez M, Nadal E, Paz-Ares L, Gu W, Felip
E, et al: 5MO: First-line adagrasib (ADA) with pembrolizumab
(PEMBRO) in patients (pts) with advanced/metastatic
KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥50%
from the phase II portion of KRYSTAL-7. J Thorac Oncol. 20 (Suppl
1):S8–S10. 2025. View Article : Google Scholar
|
|
146
|
Neal J, Pavlakis N, Kim SW, Goto Y, Lim
SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A,
et al: CONTACT-01: A randomized phase III trial of atezolizumab +
cabozantinib versus docetaxel for metastatic non-small cell lung
cancer after a checkpoint inhibitor and chemotherapy. J Clin Oncol.
42:2393–2403. 2024. View Article : Google Scholar : PubMed/NCBI
|
